Altimmune, Inc.
Altimmune, Inc. (Nasdaq: ALT) is a clinical-stage biopharmaceutical company developing therapies for serious liver diseases. Its lead product candidate, pemvidutide, is an investigational peptide that activates glucagon and GLP-1 receptors and is being studied for metabolic dysfunction-associated steatohepatitis… From the company’s description.
In fiscal 2025, Altimmune, Inc. reported revenue of $0.04M, up 105.0% from fiscal 2024, and a net loss of $88.09M. Operations used $67.53M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Altimmune, Inc. does
In the company’s own words
Altimmune, Inc. (Nasdaq: ALT) is a clinical-stage biopharmaceutical company developing therapies for serious liver diseases. Its lead product candidate, pemvidutide, is an investigational peptide that activates glucagon and GLP-1 receptors and is being studied for metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder and alcohol-associated liver disease. The company’s development program includes a Phase 2b MASH trial and Phase 2 trials for alcohol use disorder and alcohol-associated liver disease; it is preparing a Phase 3 MASH trial. Pemvidutide was acquired in 2019 through the acquisition of Spitfire Pharma, and Altimmune also holds licensed rights to technology used in the peptide. The company’s work is focused on research and clinical development rather than marketed products, and its business centers on a single lead candidate rather than reportable operating segments. More than 700 patients had received pemvidutide in completed and ongoing studies as of December 31, 2025. Its website is www.altimmune.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- MORRISTOWN, NJ
- Fiscal year end
- December
- CIK
- 1326190
- SIC
- 2834
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Altimmune, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Altimmune, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Altimmune, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Altimmune, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Altimmune, Inc.'s last four quarterly filings that the numbers alone won't show?”